Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02616679 · ClinicalTrials.gov registry record
Cognitive Detection of Preclinical AD: Validation Using Biomarkers
A clinical trial of Mild Cognitive Impairment, sponsored by NYU Langone Health.
- Completed
- Registry status
- 81
- Enrollment target
- 1
- Study location
NCT02616679: Completed study of Mild Cognitive Impairment, sponsored by NYU Langone Health.
NCT02616679 is a study of Mild Cognitive Impairment that has completed, run by NYU Langone Health. The registered enrollment target is 81 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02616679, a study of Mild Cognitive Impairment, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- 81 participants
- Enrollment target
- 1
- Study location
Study Summary
The current study aims to validate several novel cognitive tasks expected to be sensitive to brain impairment in specific anatomic regions affected in preclinical Alzheimer's disease(pAD). The tasks are validated in 60 cognitively and clinically normal participants ages 60 - 85, inclusive, against reasonably well-established biomarkers of Alzheimer's disease, including 1) simultaneous positron emission tomography (PET) \[18F\]Flutemetamol amyloid and CT imaging and 2) to the extent data is available from other studies, participants' brain MRI and cerebral spinal fluid (CSF) amyloid and tau.
Primary Outcome
The overall score on the cognitive tests will be correlated via a linear regression with biomarker data collected during the study. Each biomarker will be regressed individually. Biomarker data includes: MRI hippocampus (hipp) volume, entorhinal cortex (EC) volume, EC standard uptake value ratios (SUVRs), Hipp SUVR, precuneus (PCu) SUVR, PET-\[18F\] Flutemetamol SUVR, CSF Aβ and tau levels, levels of diffusion tensor imaging mean diffusivity, and levels of fractional anisotropy.
Conditions Studied
Study Locations (1)
New York
- NYU Langone Medical Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 81 participants |
| Start Date | 2016-01-05 |
| Est. Completion | 2020-08-12 |
What the finished NCT02616679 record still lists
NCT02616679 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 81 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (94% lower).
The record links to 1 condition, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 0 interventions.
NCT02616679 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT02616679 about?
NCT02616679 is a clinical study titled "Cognitive Detection of Preclinical AD: Validation Using Biomarkers". The current study aims to validate several novel cognitive tasks expected to be sensitive to brain impairment in specific anatomic regions affected in preclinical Alzheimer's disease(pAD). The tasks are validated in 60 cognitively and clinically normal participants ages 60 - 85, inclusive, against r...
What is the current status of trial NCT02616679?
This trial is currently completed. The enrollment target is 81 participants. The study started on 2016-01-05. Estimated completion is 2020-08-12.
What conditions does trial NCT02616679 study?
This clinical trial studies the following conditions: Mild Cognitive Impairment.
Who is sponsoring clinical trial NCT02616679?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02616679 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mild Cognitive Impairment
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02616679's enrollment target sits among peer trials
81 102nd of 205 higher than 103 of 205 other Mild Cognitive Impairment trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Wayfinding Intervention and Long-Term Memory
RECRUITING · NA
-
Psilocybin for Depression in People With Mild Cognitive Impairment or Early Alzheimer's Disease
RECRUITING · Early Phase 1
-
MCI Speech in Noise
RECRUITING
-
Dual Task Perturbation Training for OAwMCI
RECRUITING · NA
-
Determinants of Incident Stroke Cognitive Outcomes and Vascular Effects on RecoverY
RECRUITING
-
Effect of LEQEMBI on Cerebral and Retinal Amyloid in Mild Cognitive Impairment Due to Alzheimer's Disease
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04966481 · 81 participants · Phase 3
Palbociclib and Cetuximab Versus Cetuximab Monotherapy for Patients With CDKN2A-altered, HPV-unrelated Head and Neck Squamous Cell Carcinoma Who Experienced Disease Progression on a PD-1/L1 Inhibitor
- NCT05109429 · 81 participants · NA
Developing a Clinical Outcome Assessment for Opioid Craving
- NCT05112601 · 81 participants · Phase 2
Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma
- NCT05305911 · 81 participants · Phase 2
Sodium Glucose Co-Transporter 2 (SGLT2) and STEMI
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI